Literature DB >> 20188631

Experimental tuberculosis: designing a better model to test vaccines against tuberculosis.

Denise Morais Fonseca1, Rogério Silva Rosada, Marina Oliveira e Paula, Pryscilla Fanini Wowk, Luis Henrique Franco, Edson Garcia Soares, Célio Lopes Silva, Vânia Luiza Deperon Bonato.   

Abstract

Experimental models of infection are good tools for establishing immunological parameters that have an effect on the host-pathogen relationship and also for designing new vaccines and immune therapies. In this work, we evaluated the evolution of experimental tuberculosis in mice infected with increasing bacterial doses or via distinct routes. We showed that mice infected with low bacterial doses by the intratracheal route were able to develop a progressive infection that was proportional to the inoculum size. In the initial phase of disease, mice developed a specific Th1-driven immune response independent of inoculum concentration. However, in the late phase, mice infected with higher concentrations exhibited a mixed Th1/Th2 response, while mice infected with lower concentrations sustained the Th1 pattern. Significant IL-10 concentrations and a more preeminent T regulatory cell recruitment were also detected at 70 days post-infection with high bacterial doses. These results suggest that mice infected with higher concentrations of bacilli developed an immune response similar to the pattern described for human tuberculosis wherein patients with progressive tuberculosis exhibit a down modulation of IFN-gamma production accompanied by increased levels of IL-4. Thus, these data indicate that the experimental model is important in evaluating the protective efficacy of new vaccines and therapies against tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20188631     DOI: 10.1016/j.tube.2010.01.005

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  9 in total

1.  Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis.

Authors:  Carlos R Zárate-Bladés; Rodrigo F Rodrigues; Patricia R M Souza; Wendy M Rios; Luana S Soares; Rogério S Rosada; Izaíra T Brandão; Ana Paula Masson; Elaine M Floriano; Simone G Ramos; Celio L Silva
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

2.  Torticollis in mice intravenously infected with Mycobacterium tuberculosis.

Authors:  Elizabeth R Magden; Cristina M Weiner; Janet C Gilliland; Mary Ann DeGroote; Anne J Lenaerts; Lon V Kendall
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-03       Impact factor: 1.232

3.  CD11c(+)  CD103(+) cells of Mycobacterium tuberculosis-infected C57BL/6 but not of BALB/c mice induce a high frequency of interferon-γ- or interleukin-17-producing CD4(+) cells.

Authors:  Cássia A Sérgio; Thais B Bertolini; Ana Flávia Gembre; Rafael Q Prado; Vânia L D Bonato
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

4.  Genetic background affects the expansion of macrophage subsets in the lungs of Mycobacterium tuberculosis-infected hosts.

Authors:  Thais Barboza Bertolini; Alexandre Ignacio de Souza; Ana Flávia Gembre; Annie Rocio Piñeros; Rafael de Queiroz Prado; João Santana Silva; Leandra Naira Zambelli Ramalho; Vânia Luiza Deperon Bonato
Journal:  Immunology       Date:  2016-05       Impact factor: 7.397

5.  Investigation of Immune Biomarkers Using Subcutaneous Model of M. tuberculosis Infection in BALB/c Mice: A Preliminary Report.

Authors:  Aliabbas A Husain; Hatim F Daginawala; Shubangi R Warke; Devanand R Kalorey; Nitin V Kurkure; Hemant J Purohit; Girdhar M Taori; Rajpal S Kashyap
Journal:  Immune Netw       Date:  2015-04-23       Impact factor: 6.303

6.  M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection.

Authors:  A R Piñeros; L W Campos; D M Fonseca; T B Bertolini; A F Gembre; R Q Prado; J C Alves-Filho; S G Ramos; M Russo; V L D Bonato
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

7.  Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis.

Authors:  Ivan P Nascimento; Dunia Rodriguez; Carina C Santos; Eduardo P Amaral; Henrique K Rofatto; Ana P Junqueira-Kipnis; Eduardo D C Gonçalves; Maria R D'Império-Lima; Mario H Hirata; Celio L Silva; Nathalie Winter; Brigitte Gicquel; Kingston H G Mills; Mariagrazia Pizza; Rino Rappuoli; Luciana C C Leite
Journal:  Sci Rep       Date:  2017-05-18       Impact factor: 4.379

8.  CCR4-dependent reduction in the number and suppressor function of CD4+Foxp3+ cells augments IFN-γ-mediated pulmonary inflammation and aggravates tuberculosis pathogenesis.

Authors:  Thais B Bertolini; Annie R Piñeros; Rafael Q Prado; Ana Flávia Gembre; Leandra N Z Ramalho; José Carlos Alves-Filho; Vânia L D Bonato
Journal:  Cell Death Dis       Date:  2018-12-21       Impact factor: 8.469

9.  Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria.

Authors:  Carina Carvalho Dos Santos; Dunia Rodriguez; Alex Kanno Issamu; Luciana Cezar De Cerqueira Leite; Ivan Pereira Nascimento
Journal:  Hum Vaccin Immunother       Date:  2019-10-31       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.